The New York City-based private equity firm, which specializes in musculoskeletal plays, aims to fuel rapid growth via market expansion and bolt-on acquisitions, Memphis-based CrossRoads said.
The company makes a line of foot and ankle repair devices that use its “Active Stabilization” technology. The EcoSmart gamma-sterilized reusable instruments offering includes post-surgery recovery and processing services, CrossRoads said. The company launched its DynaForce Active Stabilization MPJ foot implant a year ago after winning 510(k) clearance from the FDA.
“HealthpointCapital is an ideal partner for us given their expertise and focus in the musculoskeletal space,” co-founder & CEO Vernon Hartdegen said in prepared remarks. “Our partnership strengthens our mission to be the leading innovator in the extremity foot & ankle space.”
“CrossRoads’ unique product platform, particularly its Active Stabilization technology and EcoSmart service, made them an attractive investment in the extremity sector, which continues to be one of the most rapidly growing segments of the musculoskeletal market,” added HealthpointCapital president & managing director Mike Mogul. “With our deep understanding of this space, CrossRoads’ exclusive technology made them a logical addition to our portfolio of rapidly growing companies.”
“CrossRoads’ investors are excited about this new relationship with HealthpointCapital and what it means for the future of CrossRoads. We remain holders with a substantial stake in the company’s future,” MB Venture Partners co-founder & managing partner Gary Stevenson said. “Since our initial investment four and a half years ago, management has been excellent stewards of investors’ capital creating the value that led to this transaction. We have every reason to believe they will continue to do so going forward.”
MB Venture was the lead institutional investor before the HealthpointCapital deal and, along with the management team, is still a significant backer, CrossRoads said.
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo was legal advisor to HealthpointCapital; Waller, Lansden, Dortch, & Davis advised CrossRoads.
HealthpointCapital raised $100 million last October for its Musculoskeletal Fund IV healthcare fund for investments in the orthopedics, spine, dental, maxillofacial, rehabilitation and digital health sectors. The fund has a target size of $500 million, and aims to invest in eight to ten growth-stage companies. The PE firm has some skin in companies including Blue Belt Technologies, which was acquired by Smith & Nephew (NYSE:SNN) , and BioHorizons, which was acquired by Henry Schein (NSDQ:HSIC).
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.